Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC

Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC

Source: 
Pharmaceutical Business Review
snippet: 


Roche has secured approval from the US Food and Drug Administration (FDA) for its Tecentriq (atezolizumab) plus chemotherapy for the initial treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).